Home » Stocks » Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. (ARCT)

Stock Price: $47.29 USD 0.19 (0.40%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $47.40 +0.11 (0.23%) Oct 22, 5:34 PM

Stock Price Chart

Key Info

Market Cap 1.16B
Revenue (ttm) 11.25M
Net Income (ttm) -38.46M
Shares Out 24.47M
EPS (ttm) -2.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $47.29
Previous Close $47.10
Change ($) 0.19
Change (%) 0.40%
Day's Open 46.90
Day's Range 46.69 - 50.37
Day's Volume 365,418
52-Week Range 8.51 - 66.24

More Stats

Market Cap 1.16B
Enterprise Value 1.04B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.47M
Float 18.87M
EPS (basic) -2.75
EPS (diluted) -2.52
FCF / Share -1.69
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.79M
Short Ratio 4.82
Short % of Float 20.08%
Beta 3.13
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 102.84
PB Ratio 14.44
Revenue 11.25M
Operating Income -37.94M
Net Income -38.46M
Free Cash Flow -31.81M
Net Cash 116.66M
Net Cash / Share 4.77
Gross Margin -114.19%
Operating Margin -337.10%
Profit Margin -341.80%
FCF Margin -282.66%
ROA -22.83%
ROE -66.87%
ROIC -414.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 9
Overweight 2
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$75.09*
(58.79% upside)
Low
65.0
Current: $47.29
High
82.0
Target: 75.09
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue20.7915.7513.0020.386.14----
Revenue Growth31.97%21.2%-36.23%232.06%-----
Gross Profit20.7915.7513.0020.386.14----
Operating Income-25.51-21.81-10.49-1.00-1.91-33.08-10.29-1.50-3.91
Net Income-25.99-21.79-10.90-1.57-1.90-32.83-10.55-1.58-4.11
Shares Outstanding12.0710.073.092.032.021.951.451.111.12
Earnings Per Share-2.15-2.16-3.53-0.77-0.94-16.80-7.28-1.40-3.50
Operating Cash Flow-6.45-20.76-0.46-2.868.29-28.33-7.35-1.58-2.36
Capital Expenditures-0.82-1.48-0.22-0.69-0.22-0.08-0.04--0.02
Free Cash Flow-7.26-22.24-0.68-3.558.07-28.41-7.39-1.58-2.39
Cash & Equivalents71.3536.7148.748.3550.6821.7050.100.100.57
Total Debt19.859.91-0.13---0.66-
Net Cash / Debt51.5126.8048.748.2150.6821.7050.10-0.570.57
Assets82.1444.2052.0213.7471.6822.3250.320.201.20
Liabilities56.3530.5618.2312.162.352.381.640.770.22
Book Value25.7913.6433.791.5869.3319.9448.69-0.570.99
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Arcturus Therapeutics Holdings Inc.
Country United States
Employees 88
CEO Joseph E. Payne

Stock Information

Ticker Symbol ARCT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARCT

Description

Arcturus Therapeutics Holdings, an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.